Postdoctoral Research Associate. Funded by CRUK.
Marta studied Biology in the Universitat Autònoma de Barcelona, followed by a MSc in Biomedicine in the Universitat de Barcelona. In 2006, she joined Oriol Casanovas’ laboratory at the Catalan Institute of Oncology (ICO-IDIBELL) to do her thesis. Her work in the Casanovas’ lab helped to describe an evasive resistance to the antiangiogenic therapy, which was published in 2009 in Cancer Cell (Paez-Ribes et al., 2009) and had a great impact on the field (over 1,500 citations according to the Web of Science). After the completion of her PhD she joined Professor Robert Kerbel’s laboratory in the Sunnybrook Research Institute – University of Toronto, as a postdoctoral fellow, where she contributed to the development of the first mouse model of metastatic renal cell carcinoma, which has been used in a wide range of therapeutic preclinical studies, and published in Science Translational Medicine (Jedeszko*, Paez-Ribes*, Di Desidero* et al., 2015). In 2015, she joined the University of Cambridge, first in the Department of Pathology, and later on the Muñoz-Espín’s laboratory, in the Department of Oncology. Her research now is focused on the development of novel tools for lung cancer early diagnosis and therapy.
A versatile therapeutic strategy for drug delivery into senescent cells.
Muñoz-Espín D, Rovira M, Galiana I, Giménez C, Lozano-Torres, Paez-Ribes M, Llanos S, Chaib S, Muñoz M, Ucero AC, Garaulet G, Mulero F, Dann S, VanArsdale T, Shields DJ, Bernardos A, Murguía JR, Martínez-Máñez R, Serrano M.
EMBO Molecular Medicine. 2018 Jul;10(7)
Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy.
Paez-Ribes M, Man S, Xu P, Kerbel RS.
Clin Cancer Res. 2015 Dec 15;21(24):5488-98.
Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.
Jedeszko C, Paez-Ribes M, Di Desidero T, Man S, Lee CR, Xu P, Bjarnason GA, Bocci G, Kerbel RS.
Sci Transl Med. 2015 Apr 8;7(282):282ra50.
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O.
Cancer Cell. 2009 Mar 3;15(3):220-31.